PDF herunterladen
Ultraschall Med 2022; 43(02): 115-119
DOI: 10.1055/a-1745-6879
Editorial

The Fetal Medicine Foundation (FMF) Germany after 20 Years – Quality Assurance of Ultrasound Examinations during First Trimester Screening

20 Jahre Fetal Medicine Foundation (FMF) Deutschland – Ein Beitrag zur Qualitätssicherung der Ultraschalluntersuchung beim Ersttrimester-Screening
E. Merz
1   Centre for ultrasound and prenatal medicine, Frankfurt/Main, Germany
,
Ch. Thode
2   amedes MVZ für Laboratoriumsmedizin, Göttingen, Germany
,
B. J. Hackelöer
3   Amedes experts Barkhof, Germany
,
B. Eiben
4   Institut für Laboratoriumsmedizin und Klinische Genetik, Essen, Germany
,
R. Faber
5   Centre for prenatal medicine, Leipzig, Germany
,
S. Tercanli
6   Ultraschall Freie Strasse Basel, Switzerland
,
E. Huda
7   FMF Audit Centre Germany, Adelebsen, Germany
,
S. Wellek
8   Department of Medical Biostatistics, Epidemiology and Informatics of the University of Mainz, Mainz, Germany
9   Department of Biostatistics, CIMH Mannheim, Mannheim Medical School of the University of Heidelberg, Mannheim, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

The establishment of FMF Germany on March 1, 2002 laid the foundation for nationwide quality assurance of ultrasound examinations for first trimester screening. This was preceded by four meetings in Frankfurt with participants from the fields of prenatal diagnostics, laboratory medicine, human genetics and medical software development, in order to plan the possibilities of introducing from the outset first trimester screening in Germany to the highest possible standard. With the constitutive meeting of FMF Germany on March 1, 2002, an independent non-profit association for the promotion of prenatal medicine in Germany was established, following FMF London and in cooperation with the German Society for Ultrasound in Medicine (DEGUM). Prenatal DEGUM Level III physicians, laboratory physicians and human geneticists were elected as board members. Founding members and founding board members are listed on page 119.



Publikationsverlauf

Artikel online veröffentlicht:
05. April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Snijders RJ, Noble P, Sebire N. et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346
    CrossrefPubMedSuche in Google Scholar
  • 2 Nicolaides KH, Cicer S, Liao AW. One stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation. Prenat Neonat Med 2000; 5: 145-154
    PubMedSuche in Google Scholar
  • 3 Spencer K, Souter V, Tul N. et al. A rapid screening program for trisomy 21 at 10-14 weeks using fetal nuchal tranclucency, maternal serum free ß-hCG and PAPP-A. Ultrasound Obstet Gynecol 1999; 13: 231-237
    CrossrefPubMedSuche in Google Scholar
  • 4 Cicero S, Avgidou K, Rembouskos G. et al. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195 (01) 109-114
    CrossrefPubMedSuche in Google Scholar
  • 5 Faiola S, Tsoi E, Huggon IC. et al. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan. Ultrasound Obstet Gynecol 2005; 26 (01) 22-27
    CrossrefPubMedSuche in Google Scholar
  • 6 Kagan KO, Valencia C, Livanos P. et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33 (01) 18-22
    CrossrefPubMedSuche in Google Scholar
  • 7 Borrell A, Gonce A, Martinez JM. et al. First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn 2005; 25 (10) 901-905
    CrossrefPubMedSuche in Google Scholar
  • 8 Merz E, Thode C, Alkier A. et al. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med 2008; 29 (06) 639-645
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Merz E, Thode C, Eiben B. et al. Individualized correction for maternal weight in calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med 2011; 32 (01) 33-39
    Thieme ConnectPubMedSuche in Google Scholar
  • 10 Merz E, Thode C, Eiben B. et al. Prenatal Risk Calculation (PRC) 3.0: An extended DoE-based first-trimester screening algorithm allowing for early blood sampling. Ultrasound Int Open 2016; 2 (01) E19-E26
    Thieme ConnectPubMedSuche in Google Scholar
  • 11 Lo YM, Chan KC, Sun H. et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010; 2 (61) 61ra91
    CrossrefPubMedSuche in Google Scholar
  • 12 Eiben B, Krapp M, Borth H. et al. Single nucleotide polymorphism-based analysis of cell-free fetal DNA in 3000 cases from Germany and Austria. Ultrasound Int Open 2015; 1 (01) E8-E11
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Syngelaki A, Chelemen T, Dagklis T. et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011; 31 (01) 90-102
    CrossrefPubMedSuche in Google Scholar
  • 14 Kagan KO, Hoopmann M, Hammer R. et al. Screening for chromosomal abnormalities by first trimester combined screening and noninvasive prenatal testing. Ultraschall Med 2015; 36 (01) 40-46
    Thieme ConnectPubMedSuche in Google Scholar
  • 15 Schmid M, Klaritsch P, Arzt W. et al. Cell-free DNA testing for fetal chromosomal anomalies in clinical practice: Austrian-German-Swiss recommendations for non-invasive prenatal tests (NIPT). Ultraschall Med 2015; 36 (05) 507-510
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Kozlowski P, Burkhardt T, Gembruch U. et al. DEGUM, ÖGUM, SGUM and FMF Germany recommendations for the implementation of first-trimester screening, detailed ultrasound, cell-free DNA screening and diagnostic procedures. Ultraschall Med 2019; 40 (02) 176-193
    Thieme ConnectPubMedSuche in Google Scholar